title: Xerostomia in long-term survivors of aggressive non-Hodgkin's lymphoma of Waldeyer's ring: a potential role for parotid-sparing techniques?
abstract: BACKGROUND
  The degree of xerostomia in patients treated for intermediate-and high-grade non-Hodgkin lymphoma (NHL) of Waldeyer's ring (WR) is unknown.
  
  
  METHODS
  Fifteen patients treated for stage I-IV NHL of WR with radiotherapy (RT) were administered a xerostomia questionnaire. Numerical responses (0 = no xerostomia; 100 = maximum xerostomia) were compared with responses from 5 sets of patients treated for head and neck squamous cell carcinoma who were grouped by amount of parotid in RT field: larynx-only, ipsilateral parotid, bilateral-partial parotid, bilateral-total parotid, parotid-sparing intensity-modulated radiotherapy.
  
  
  RESULTS
  Waldeyer's patients' median xerostomia questionnaire score was 31, which was significantly different from the larynx-only group, bilateral-partial parotid group, and bilateral-total parotid group, but not significantly different from the ipsilateral parotid group or parotid-sparing intensity-modulated radiotherapy group.
  
  
  CONCLUSIONS
  Xerostomia in survivors WR NHL is a detectable toxicity with severity like that in head and neck squamous cell carcinoma patients who receive ipsilateral parotid irradiation, and warrants parotid-sparing RT techniques.
authors.affiliation: Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Chang
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Amdur
authors.forename: Heather
authors.initials: H
authors.lastname: Pacholke
authors.forename: Nancy P
authors.initials: NP
authors.lastname: Mendenhall
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Morris
authors.forename: Gracie A
authors.initials: GA
authors.lastname: Byer
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Olivier
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D020522:Lymphoma, Mantle-Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010306:Parotid Gland / Q000528:radiation effects*; D011379:Prognosis; D011832:Radiation Injuries / Q000209:etiology* / Q000473:pathology; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated; D011795:Surveys and Questionnaires; D017741:Survivors; D016896:Treatment Outcome; D014987:Xerostomia / Q000209:etiology* / Q000473:pathology; D055815:Young Adult